Roche/Genentech's Avastin took another step toward an indication in ovarian cancer with the July 2 release of positive top-line results from a second Phase III study showing a benefit in progression free survival. At the American Society of Clinical Oncology annual meeting in June, the first Phase III study of Avastin (bevacizumab) in ovarian cancer was presented as a plenary presentation. The GOG 0218 study of 1,873 women (most enrolled in the U.S.) found Avastin improved progression-free survival...